Immunomodulation of human intestinal t cells by the synthetic cd80 antagonist rhudexw

Immunity, Inflammation and Disease

Volumn 2, Issue 3, 2014, Pages 166-180

  Heninger, Anne Kristin ^a   Wentrup, Sabine ^a   Al Saeedi, Mohammed ^a   Schiessling, Serin ^a   Giese, Thomas ^a   Wartha, Florian ^b   Meuer, Stefan ^a   Schröder Braunstein, Jutta ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b MediGene AG   (Germany)

Author keywords

CD80 blockage; Immunomodulation; Inflammatory bowel disease; Mucosal immunology; T cells

Indexed keywords

EID: 85019300752     PISSN: None     EISSN: 20504527     Source Type: Journal    
DOI: 10.1002/iid3.34     Document Type: Article

References (57)

1. Bosani, M., S. Ardizzone, and G. B. Porro. 2009. Biologic targeting in the treatment of inflammatory bowel diseases. Biologics 3:77–97.
2. Baert, F., M. Noman, S. Vermeire, G. Van Assche, D. H. G, A. Carbonez, and P. Rutgeerts. 2003. Influence of immunoge-nicity on the long-term efficacy of infliximab in Crohn’s disease. N. Engl. J. Med. 348(7):601–608.
3. Pirzer, U. C., G. Schurmann, S. Post, M. Betzler, and S. C. Meuer. 1990. Differential responsiveness to CD3-Ti vs. CD2-dependent activation of human intestinal T lymphocytes. Eur. J. Immunol. 20(10):2339–2342.
4. Meuer, S. C., R. E. Hussey, M. Fabbi, D. Fox, O. Acuto, K. A. Fitzgerald, J. C. Hodgdon, J. P. Protentis, S. F. Schlossman, and E. L. Reinherz. 1984. An alternative pathway of T-cell activation: a functional role for the 50 kd T11 sheep erythrocyte receptor protein. Cell 36(4):897–906.
5. Hunig, T., G. Tiefenthaler, K. H. Meyer zum Buschenfelde, and S. C. Meuer. 1987. Alternative pathway activation of T cells by binding of CD2 to its cell-surface ligand. Nature 326(6110):298–301.
6. Braunstein, J., F. Autschbach, T. Giese, F. Lasitschka, A. Heidtmann, B. Sido, B. Funke, C. Reiser, A. J. Schroder, G. Nebl, et al. 2008. Up-regulation of the phosphoinositide 3-kinase pathway in human lamina propria T lymphocytes. Clin. Exp. Immunol. 151(3):496–504.
7. Boirivant, M., I. Fuss, C. Fiocchi, J. S. Klein, S. A. Strong, and W. Strober. 1996. Hypoproliferative human lamina propria T cells retain the capacity to secrete lymphokines when stimulated via CD2/CD28 pathways. Proc. Assoc. Am. Physicians 108(1):55–67.
8. Liu, Z., K. Geboes, P. Hellings, P. Maerten, H. Heremans, P. Vandenberghe, L. Boon, P. van Kooten, P. Rutgeerts, and J. L. Ceuppens. 2001. B7 interactions with CD28 and CTLA-4 control tolerance or induction of mucosal inflammation in chronic experimental colitis. J. Immunol. 167(3):1830–1838.
9. Sido, B., F. Lasitschka, T. Giese, N. Gassler, B. Funke, J. Schroder-Braunstein, U. Brunnemer, S. C. Meuer, and F. Autschbach. 2008. A prominent role for mucosal cystine/ cysteine metabolism in intestinal immunoregulation. Gastroenterology 134(1):179–191.
10. Qiao, L., M. Golling, F. Autschbach, G. Schurmann, and S. C. Meuer. 1994. T cell receptor repertoire and mitotic responses of lamina propria T lymphocytes in inflammatory bowel disease. Clin. Exp. Immunol. 97(2):303–308.
11. Rugtveit, J., A. Bakka, and P. Brandtzaeg. 1997. Differential distribution of B7.1 (CD80) and B7.2 (CD86) costimulatory molecules on mucosal macrophage subsets in human inflammatory bowel disease (IBD). Clin. Exp. Immunol. 110(1):104–113.
12. Huxley, P., D. H. Sutton, P. Debnam, I. R. Matthews, J. E. Brewer, J. Rose, M. Trickett, D. D. Williams, T. B. Andersen, and B. J. Classon. 2004. High-affinity small molecule inhibitors of T cell costimulation: compounds for immunotherapy. Chem. Biol. 11(12):1651–1658.
13. Schroder-Braunstein, J., J. Gras, B. Brors, S. Schwarz, T. Szikszai, F. Lasitschka, G. Wabnitz, A. Heidtmann, Y.S. Lee, S. Schiessling, et al. 2014. Initiation of an inflammatory response in resident intestinal lamina propria cells—use of a human organ culture model. PLoS ONE 9(5):e97780.
14. Linsley, P. S., and S. G. Nadler. 2009. The clinical utility of inhibiting CD28-mediated costimulation. Immunol. Rev. 229(1):307–321.
15. Mahida, Y. R., A. M. Galvin, T. Gray, S. Makh, M. E. McAlindon, H. F. Sewell, and D. K. Podolsky. 1997. Migration of human intestinal lamina propria lymphocytes, macrophages and eosinophils following the loss of surface epithelial cells. Clin. Exp. Immunol. 109(2):377–386.
16. Battifora, M., G. Pesce, F. Paolieri, N. Fiorino, C. Giordano, A.M. Riccio, G. Torre, D. Olive, and M. Bagnasco. 1998. B7.1 costimulatory molecule is expressed on thyroid follicular cells in Hashimoto’s thyroiditis, but not in Graves’ disease. J. Clin. Endocrinol. Metab. 83(11):4130–4139.
17. Sido, B., J. Braunstein, R. Breitkreutz, C. Herfarth, and S. C. Meuer. 2000. Thiol-mediated redox regulation of intestinal lamina propria T lymphocytes. J. Exp. Med. 192(6):907–912.
18. Fujino, S., A. Andoh, S. Bamba, A. Ogawa, K. Hata, Y. Araki, T. Bamba, and Y. Fujiyama. 2003. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52(1): 65–70.
19. Camoglio, L., A. A. Te Velde, A. J. Tigges, P. K. Das, and S. J. Van Deventer. 1998. Altered expression of interferon-gamma and interleukin-4 in inflammatory bowel disease. Inflamm. Bowel Dis. 4(4):285–290.
20. Izcue, A., J. L. Coombes, and F. Powrie. 2009. Regulatory lymphocytes and intestinal inflammation. Annu. Rev. Immunol. 27:313–338.
21. Imai, K., and A. Takaoka. 2006. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 6(9): 714–727.
22. Chen, L., and D. B. Flies. 2013. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13(4):227–242.
23. Lenschow, D. J., T. L. Walunas, and J. A. Bluestone. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14:233–258.
24. Linsley, P. S., W. Brady, L. Grosmaire, A. Aruffo, N. K. Damle, and J. A. Ledbetter. 1991. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 173(3):721– 730.
25. Powell, J. D., J. A. Ragheb, S. Kitagawa-Sakakida, and R. H. Schwartz. 1998. Molecular regulation of interleukin-2 expression by CD28 co-stimulation and anergy. Immunol. Rev. 165:287–300.
26. Boise, L. H., A. J. Minn, P. J. Noel, C. H. June, M. A. Accavitti, T. Lindsten, and C. B. Thompson. 1995. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 3(1):87–98.
27. Fleischer, J., E. Soeth, N. Reiling, E. Grage-Griebenow, H. D. Flad, and M. Ernst. 1996. Differential expression and function of CD80 (B7-1) and CD86 (B7-2) on human peripheral blood monocytes. Immunology 89(4):592–598.
28. Salomon, B., and J. A. Bluestone. 2001. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19:225– 252.
29. Pentcheva-Hoang, T., J. G. Egen, K. Wojnoonski, and J. P. Allison. 2004. B7-1 and, B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 21(3):401– 413.
30. Collins, A.V., D. W. Brodie, R. J. Gilbert, A. Iaboni, R. Manso-Sancho, B. Walse, D. I. Stuart P. A. van der Merwe and S. J. Davis. 2002. The interaction properties of costimulatory molecules revisited. Immunity 17(2):201–210.
31. Lenschow, D. J., S. C. Ho, H. Sattar, L. Rhee, G. Gray, N. Nabavi, K. C. Herold, and J. A. Bluestone. 1995. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 181(3):1145–1155.
32. Lang, T. J., P. Nguyen, R. Peach, W. C. Gause, and C. S. Via. 2002. In vivo CD86 blockade inhibits CD4þ T cell activation, whereas CD80 blockade potentiates CD8þ T cell activation and CTL effector function. J. Immunol. 168(8):3786–3792.
33. Brunet, J. F., F. Denizot, M. F. Luciani, M. Roux-Dosseto, M. Suzan, M. G. Mattei, and P. Golstein. 1987. A new member of the immunoglobulin superfamily—CTLA-4. Nature 328(6127):267–270.
34. Rudd, C. E., A. Taylor, and H. Schneider. 2009. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol. Rev. 229(1):12–26.
35. Fukai, T., A. A. Okada, J. Sakai, T. Kezuka, H. Keino, M. Usui, H. Yagita, K. Okumura, and J. Mizuguchi. 1999. The role of costimulatory molecules B-1 and B7-2 in mice with experimental autoimmune uveoretinitis. Graefes Arch. Clin. Exp. Ophthalmol. 237(11):928–933.
36. Kuchroo, V. K., M. P. Das, J. A. Brown, A. M. Ranger, S. S. Zamvil, R. A. Sobel, H. L. Weiner, N. Nabavi, and L. H. Glimcher. 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80(5):707– 718.
37. Eri, R., K. N. Kodumudi, D. J. Summerlin, and M. Srinivasan. 2008. Suppression of colon inflammation by CD80 blockade: evaluation in two murine models of inflammatory bowel disease. Inflamm. Bowel Dis. 14(4):458–470.
38. Ruperto, N., D. J. Lovell, P. Quartier, E. Paz, N. Rubio-Perez, C. A. Silva, C. Abud-Mendoza, R. Burgos-Vargas, V. Gerloni, J. A. Melo-Gomes, et al. 2008. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 372(9636):383– 391.
39. Genovese, M. C., J. C. Becker, M. Schiff, M. Luggen, Y. Sherrer, J. Kremer, C. Birbara, J. Box, K. Natarajan, I. Nuamah, et al. 2005. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 353(11):1114–1123.
40. Sandborn, W. J., J. F. Colombel, B. E. Sands, P. Rutgeerts, S. R. Targan, R. Panaccione, B. Bressler, K. Geboes, S. Schreiber, R. Aranda, et al. 2012. Abatacept for Crohn’s disease and ulcerative colitis. Gastroenterology 143(1):62–69. e64.
41. Davenport, C. M., H. A. McAdams, J. Kou, K. Mascioli, C. Eichman, L. Healy, J. Peterson, S. Murphy, D. Coppola, and A. Truneh. 2002. Inhibition of pro-inflammatory cytokine generation by CTLA4-Ig in the skin and colon of mice adoptively transplanted with CD45RBhi CD4þ T cells correlates with suppression of psoriasis and colitis. Int. Immunopharmacol. 2(5):653–672.
42. Poussier, P., T. Ning, J. Chen, D. Banerjee, and M. Julius. 2000. Intestinal inflammation observed in IL-2R/IL-2 mutant mice is associated with impaired intestinal T lymphopoiesis. Gastroenterology 118(5):880–891.
43. Fontenot, J. D. J. P. Rasmussen, M. A. Gavin, and A. Y. Rudensky. 2005. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6(11):1142– 1151.
44. Setoguchi, R., S. Hori, T. Takahashi, and S. Sakaguchi. 2005. Homeostatic maintenance of natural Foxp3(þ) CD25(þ) CD4(þ) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 201(5):723–735.
45. de la Rosa, M., S. Rutz, H. Dorninger, and A. Scheffold. 2004. Interleukin-2 is essential for CD4þ CD25þ regulatory T cell function. Eur. J. Immunol. 34(9):2480–2488.
46. Makita, S., T. Kanai, S. Oshima, K. Uraushihara, T. Totsuka, T. Sawada, T. Nakamura, K. Koganei, T. Fukushima, and M. Watanabe. 2004. CD4þ CD25bright T cells in human intestinal lamina propria as regulatory cells. J. Immunol. 173(5):3119–3130.
47. Wing, K., Y. Onishi, P. Prieto-Martin, T. Yamaguchi, M. Miyara, Z. Fehervari, T. Nomura, and S. Sakaguchi. 2008. CTLA-4 control over Foxp3þ regulatory T cell function. Science 322(5899):271–275.
48. Mora, J. R., and U. H. von Andrian. 2006. T-cell homing specificity and plasticity: new concepts and future challenges. Trends Immunol. 27(5):235–243.
49. 1 in patients with rheumatoid arthritis, in 36th Annual Meeting of the German Society for Rheumatology.
50. Newell, K. A., G. He, Z. Guo, O. Kim, G.L. Szot, I. Rulifson, P. Zhou, J. Hart, J. R. Thistlethwaite, and J. A. Bluestone. 1999. Cutting edge: blockade of the CD28/B7 costimulatory pathway inhibits intestinal allograft rejection mediated by CD4þ but not CD8þ T cells. J. Immunol. 163(5):2358– 2362.
51. Reddy, B., S. Gupta, Y. Chuzhin, A. M. Kalergis, L. Budhai, M. Zhang, G. Droguett, M. S. Horwitz, J. R. Chowdhury, S. G. Nathenson, et al. 2001. The effect of CD28/B7 blockade on alloreactive T and B cells after liver cell transplantation. Transplantation 71(6):801–811.
52. Maynard, C. L., and C. T. Weaver. 2009. Intestinal effector T cells in health and disease. Immunity 31(3):389–400.
53. Targan, S. R., R. L. Deem, M. Liu, S. Wang, and A. Nel. 1995. Definition of a lamina propria T cell responsive state. Enhanced cytokine responsiveness of T cells stimulated through the CD2 pathway. J. Immunol. 154(2):664–675.
54. Grohmann, U., C. Orabona, F. Fallarino, C. Vacca, F. Calcinaro, A. Falorni, P. Candeloro, M.L. Belladonna, R. Bianchi, M. C. Fioretti, et al. 2002. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 3(11):1097– 1101.
55. Rogler, G., M. Hausmann, D. Vogl, E. Aschenbrenner, T. Andus, W. Falk, R. Andreesen, J. Scholmerich, and V. Gross. 1998. Isolation and phenotypic characterization of colonic macrophages. Clin. Exp. Immunol. 112(2):205–215.
56. Qiao, L., J. Braunstein, M. Golling, G. Schurmann, F. Autschbach, P. Moller, and S. Meuer. 1996. Differential regulation of human T cell responsiveness by mucosal versus blood monocytes. Eur. J. Immunol. 26(4):922–927.
57. Haanstra, K. G., J. Endell, D. Estevao, I. Kondova, and M. Jonker. 2009. Blocking T cell co-stimulation using a CD80 blocking small molecule reduces delayed type hypersensitivity responses in rhesus monkeys. Clin. Exp. Immunol. 158(1): 91–98.